Neurocrine Biosciences to Present at Upcoming Investor Conferences in May

Rhea-AI Summary

Neurocrine Biosciences (NASDAQ: NBIX) has announced its participation in two major investor conferences in May 2025. CEO Kyle Gano and VP of Investor Relations Todd Tushla will present at the BofA Securities 2025 Health Care Conference on May 13 at 11:20 AM PT in Las Vegas. Additionally, CFO Matt Abernethy and CCO Eric Benevich will present at the RBCCM Global Healthcare Conference on May 20 at 11:30 AM ET in New York. Both presentations will be available via webcast on the company's website, with replays accessible for approximately one month. Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company with FDA-approved treatments for various neurological conditions, including tardive dyskinesia, Huntington's disease chorea, and endometriosis.

SAN DIEGO, May 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in May.

• Chief Executive Officer Kyle Gano and Vice-President of Investor Relations Todd Tushla will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 at 11:20 AM Pacific Time in Las Vegas.
• Chief Financial Officer Matt Abernethy and Chief Commercial Officer Eric Benevich will present at the RBCCM Global Healthcare Conference on Tuesday, May 20, 2025 at 11:30 AM Eastern Time in New York.

The live webcasts can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcasts will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.

About Neurocrine Biosciences

Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes U.S. FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (Formerly Twitter) and Facebook.                                                                           (*in collaboration with AbbVie)

The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-upcoming-investor-conferences-in-may-302447740.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When is Neurocrine Biosciences (NBIX) presenting at the BofA Securities Healthcare Conference in 2025?

Neurocrine Biosciences will present at the BofA Securities Healthcare Conference on Tuesday, May 13, 2025, at 11:20 AM Pacific Time in Las Vegas.

Who will represent NBIX at the RBCCM Global Healthcare Conference in May 2025?

CFO Matt Abernethy and Chief Commercial Officer Eric Benevich will represent Neurocrine Biosciences at the RBCCM Global Healthcare Conference.

How can investors access Neurocrine Biosciences' conference presentations in May 2025?

Investors can access the live webcasts through Neurocrine Biosciences' website under the Investors section at www.neurocrine.com. Replays will be available for approximately one month after the events.

What are the main FDA-approved treatments offered by Neurocrine Biosciences (NBIX)?

Neurocrine Biosciences has FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids.